CLN-049 for Relapsed/Refractory Acute Myeloid Leukemia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Emory University Hospital, Atlanta, GARelapsed/Refractory Acute Myeloid Leukemia+2 MoreCLN-049 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial tests a new drug to treat relapsed/refractory AML/MDS, a type of blood cancer.

Eligible Conditions
  • Relapsed/Refractory Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Relapsed or Refractory Acute Myeloid Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

5 Primary · 1 Secondary · Reporting Duration: 28 Days

28 Days
Cmax of CLN-049
Ctrough of CLN-049
Tmax of CLN-049
28 days
Immunogenicity of CLN-049
Therapeutic procedure
Up to 28 days
T1/2 of CLN-049

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

4 Treatment Groups

Part C - Multiple ascending dose (MAD) design of SC administered CLN-049
1 of 4
Part A - Single ascending dose (SAD) design of IV administered CLN-049
1 of 4
Part B - Multiple ascending dose (MAD) design of IV administered CLN-049
1 of 4
Single Ascending Dose (SAD)
1 of 4

Experimental Treatment

60 Total Participants · 4 Treatment Groups

Primary Treatment: CLN-049 · No Placebo Group · Phase 1

Part C - Multiple ascending dose (MAD) design of SC administered CLN-049
Drug
Experimental Group · 1 Intervention: CLN-049 · Intervention Types: Drug
Part A - Single ascending dose (SAD) design of IV administered CLN-049
Drug
Experimental Group · 1 Intervention: CLN-049 · Intervention Types: Drug
Part B - Multiple ascending dose (MAD) design of IV administered CLN-049
Drug
Experimental Group · 1 Intervention: CLN-049 · Intervention Types: Drug
Single Ascending Dose (SAD)
Drug
Experimental Group · 1 Intervention: CLN-049 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

Cullinan Oncology, LLCLead Sponsor
3 Previous Clinical Trials
708 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have tried other approved treatments that didn't work or caused unwanted side effects, or you have chosen not to try these treatments.

Frequently Asked Questions

What is the upper limit for participants in this clinical experiment?

"This medical trial demands the enrollment of 60 individuals who meet its entry requirements. Potential participants can be found at either Emory University Hospital in Atlanta, Georgia or UCLA in Los Angeles, California." - Anonymous Online Contributor

Unverified Answer

How many sites in Canada are conducting this clinical research?

"The trial is currently inviting participants to join from 7 different medical sites, located in several cities including Atlanta, Los Angeles and Tampa. It may be advantageous for you if the closest centre to your area of residence participates so as to reduce travel demands." - Anonymous Online Contributor

Unverified Answer

What perils could individuals face when exposed to CLN-049?

"CLN-049's safety profile has been evaluated as a 1 on the Power scale due to it being in its initial clinical testing stage, where data supporting efficacy and safety is still limited." - Anonymous Online Contributor

Unverified Answer

Are there still vacancies available to participate in this experiment?

"Affirmative. The information found on clinicaltrials.gov confirms that the trial is recruiting participants, with an original posting date of November 18th 2021 and a recent update on December 6th 2022. This study needs to acquire 60 individuals from 7 distinct locations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.